Amgen Inc.
Variant activin receptor

Last updated:

Abstract:

The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.

Status:
Grant
Type:

Utility

Filling date:

25 Sep 2017

Issue date:

10 Sep 2019